Publisher
Springer International Publishing
Reference23 articles.
1. Tracy CM, Epstein AE, Darbar D et al. ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac Rhythm Abnormalities. A report of the American College of Cardiology Foundation/American Heart association task force on practice guidelines and the Heart Rhythm society. 2012; 61:e6–e75.
2. Russo AM, Stainback RF, Bailey SR et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy. A report of the American College of Cardiology foundation appropriate use criteria task force, heart Rhythm society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, society for cardiovascular angiography and interventions, society of cardiovascular computed tomography, and society for cardiovascular magnetic resonance (2013); 61:1318–1368.
3. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014;130:94–125.
4. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72:e91–220.
5. AvIDA Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–84.